About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Active Not RecruitingNANCT04867681

Study of the Impact on the Therapeutic Alliance of a Short Initial Psychoeducation Programme in Patients With Early Schizophrenia

Schizophrenia is a serious, disabling and unfortunately common disease. Its prevalence is in the order of 0.6 to 1% in the general population, a figure that remains relatively stable in the various cu...

Lead sponsor: Centre Hospitalier Universitaire de Nice•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Centre Hospitalier Universitaire de Nice

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•French speaking
•Presenting a first or second acute psychotic episode, corresponding according to DSM 5 criteria to:
•* A brief psychotic disorder
•* And/or a schizophrenic disorder evolving for less than 2 years,
•Hospitalized in full time or in day care,
•Understanding and accepting the constraints of the study,

Exclusion Criteria

•Patient under guardianship
•Patient participating in another study
•Patient in hospital under restraint

Related studies

RECRUITINGPhase 3

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212 · Schizophrenia

Accelerated Transcranial Magnetic Stimulation for People With Schizophrenia Treated With Clozapine

NCT06003036 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Synbiotic Compound to Reduce Symptoms of Schizophrenia

NCT04226898 · Schizophrenia, Schizoaffective Disorder

RECRUITINGPhase 2

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

NCT05052853 · Prodromal Schizophrenia

RECRUITINGPhase 2

Combination of NMDA-enhancing and Anti-inflammatory Treatments for Ultra-resistant Schizophrenia

NCT05240976 · Schizophrenia

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: July 14, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhaseNA

Enrollment40

Start dateDec 2021

Last updatedJul 14, 2025

Condition

Locations shown

CHU de Nice

Nice

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 14, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions